News

elegslab has been selected for the Gyeonggi-do Open Innovation Program, an initiative connecting major corporations with promising startups. The core of this strategy lies in building an 'AI-integrated, next-generation preclinical platform' through open innovation projects. elegslab is one of four key participants, contributing its 'In vivo ADME & Efficacy Evaluation alternative testing platform.' Woojung Bio plans to integrate elegslab's innovative technology with its own preclinical CRO expertise and accelerating capabilities to develop a highly scalable and advanced preclinical solution.

http://www.hitnews.co.kr/news/articleView.html?idxno=65359

https://health.chosun.com/news/dailynews_view.jsp?mn_idx=553769